Project description
A novel approach for the development of cancer vaccines
Immunotherapy is a promising approach for treating cancer, but so far, cancer vaccines have demonstrated limited success in clinical trials. Recently, the identification of aberrant tumour-associated carbohydrate antigens (TACAs) on the surface of cancer cells has spurred the development of novel cancer vaccines. The EU-funded ARGONAUT project aims to address the problems associated with the development of effective vaccine candidates through novel technologies. The focus will be on vaccines based on ganglioside-type TACAs that are easy to formulate and can elicit an immune response independent of individual genetic variations. The project will offer the possibility for a more tumour-selective immunotherapy approach.
Fields of science
- medical and health sciencesclinical medicineoncologylung cancer
- medical and health sciencesclinical medicineoncologyskin cancermelanoma
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines
- natural sciencesbiological sciencesbiochemistrybiomoleculescarbohydrates
- medical and health sciencesbasic medicineimmunologyimmunotherapy
Programme(s)
Funding Scheme
MSCA-IF-EF-ST - Standard EF
Coordinator
2800 Kongens Lyngby
Denmark
See on map